NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone Biologic (NRXBF) reported laboratory results showing similar, dose-dependent anti-inflammatory activity across three separately produced batches of its naïve exosomes.
At the highest tested concentration, average reductions in the inflammation-related proteins IL-6 and TNF-α reached approximately 88% and 57%, respectively, relative to the inflammation-stimulated control. The study used laboratory macrophages, a type of immune cell. Responses were similar across batches, with some variability, particularly for TNF-α at intermediate concentrations. These findings do not establish clinical anti-inflammatory efficacy.
The company views the results as supporting ExoPTEN development and planned commercial exosome supply through Exo-Top. NurExone is advancing its U.S. production strategy with Made Scientific, focusing on scalability and reproducible biological activity.
NurExone Biologic (NRXBF) doubled exosome output by operating two bioreactors in parallel without increasing overall production time, while maintaining process consistency.
The parallel run achieved 200% relative yield, versus 100% for each single-reactor run, with comparable exosome quality. All runs showed the same identity markers, more than 95% protein-impurity removal and comparable anti-inflammatory activity. These are manufacturing results, not clinical outcomes.
NurExone plans to expand capacity by adding standardized production units rather than larger vessels, through its wholly owned U.S. subsidiary Exo-Top and collaboration with Made Scientific. The company sees potential capital and development-timeline benefits, subject to successful validation and implementation. Its strategy combines therapeutic development with potential commercial opportunities for naïve exosomes outside its drug pipeline.
NurExone (NRXBF) announced positive preclinical optic nerve injury results supporting plans to advance its program into larger-animal studies.
In a rat optic nerve crush model, ExoPTEN improved retinal electrical responses versus injured control eyes at the higher light level tested (p = 0.04). Naïve exosomes, which carry no added therapeutic cargo, reached approximately 5 microvolts, the measurable-response threshold; ExoPTEN exceeded it and controls remained below it. No statistically significant difference between the treatments was reported. The model does not reproduce all features of human glaucoma.
NurExone plans a rabbit study to assess delivery, dosing, tolerability and safety, subject to final protocol development, funding and regulatory approvals. Separately, its corrected RedChip agreement has a 180-day term beginning September 30, 2026, following TSXV approval, rather than the previously disclosed 90-day term.
NurExone Biologic (NRXBF) will expand its U.S. presence with CEO Dr. Lior Shaltiel and R&D Director Dr. Tali Kizhner participating in four Boston life sciences events from September 22–25, 2026.
They will speak at the 8th Exosome-Based Therapeutics Development Summit, LSX Congress USA and BioProcess International, and Shaltiel will attend the invitation-only World Medical Innovation Forum. The company is advancing its lead exosome-based candidate ExoPTEN toward clinical development for acute spinal cord injury and pursuing U.S. manufacturing initiatives. NurExone also entered a non-exclusive investor relations agreement with RedChip Companies for a two-week U.S. TV campaign of about 40 airings, with a one-time cash fee of US$65,000, subject to TSX Venture Exchange acceptance.
NurExone Biologic (NRXBF) reported that shareholders approved all resolutions at the September 15, 2026 annual general and special meeting, including a board authorization to implement a share consolidation of up to 30 pre-consolidation shares for each one post-consolidation share within 36 months, subject to TSXV and other approvals.
All five director nominees were re-elected with support ranging from 95.37% to 99.96% of votes cast. Shareholders reappointed Ziv Haft, a BDO member firm, as auditor with 99.95% support. Disinterested shareholders re-approved the amended and restated omnibus equity incentive plan with 99.17% of votes cast, and the consolidation resolution received 97.61% support and exceeded the required 66⅔% threshold. The company also entered a 12‑month, cash-only investor relations and capital markets consulting agreement with Acorn Management Partners, with maximum aggregate base fees of US$180,000, subject to TSXV acceptance.
NurExone (NRXBF) signed a non-binding Memorandum of Understanding with NanoPass Technologies to evaluate combining NurExone’s MSC-derived exosome formulations with NanoPass’s FDA-cleared MicronJet™ delivery platform for ophthalmic and dermatology/aesthetic uses.
In ophthalmology, the partners plan a preclinical study of MicronJet™ for suprachoroidal delivery of ExoPTEN for optic nerve damage, comparing it with existing administration methods. In dermatology and aesthetics, they will assess intradermal delivery of exosomes for applications such as skin rejuvenation, aiming to overcome the skin barrier. Each company will fund its own work; NurExone will own preclinical proof-of-concept results, while any newly developed intellectual property will be jointly owned. The MOU can be terminated by either party with 30 days’ written notice.
NurExone (OTCQB: NRXBF) has called an annual general and special meeting for September 15, 2026 in Toronto to seek shareholder approval for a special resolution authorizing a share consolidation of up to 30 pre-consolidation shares for 1 post-consolidation share. If approved by at least 66⅔% of votes cast, the board would have discretion to implement the consolidation at a chosen ratio and time within 36 months, subject to TSXV acceptance and other approvals, or to decide not to proceed.
The board links the proposed consolidation to NurExone’s evaluation of potential U.S. capital markets alternatives, including a possible future listing on a major U.S. exchange, and highlights both potential benefits and liquidity risks, noting there is no assurance of any price or listing outcome.
NurExone (OTCQB: NRXBF) closed a non-brokered private placement of 1,938,326 units at C$0.55 per unit, raising gross proceeds of approximately C$1,066,078, subject to final TSX Venture Exchange acceptance. Proceeds are intended for general working capital.
Each unit includes one common share and one warrant. Each warrant allows purchase of one share at C$0.69 for 36 months, with an acceleration feature if the 20-day VWAP reaches C$1.38. All securities are subject to a hold period until December 21, 2026. NurExone develops exosome-based regenerative therapies, led by its preclinical candidate ExoPTEN for acute spinal cord and optic nerve damage.
NurExone (OTCQB: NRXBF) reported new preclinical tissue-analysis data for its exosome-based candidate ExoPTEN in an acute spinal cord injury animal model. Using spinal cord tissue from a prior efficacy study, researchers found significantly higher numbers of Myelin Basic Protein (MBP)-positive cells in ExoPTEN-treated animals versus controls two months after injury.
The increase in MBP-positive cells, a marker of myelin, was statistically significant in both rostral (p=0.01) and caudal (p=0.04) regions, adding biological support for ExoPTEN’s potential neuroprotective effect and previously reported functional recovery. NurExone also announced a conditional, cash-paid investor awareness agreement with BullVestor for Austria, Germany and Switzerland, including a C$2,500 monthly program and optional campaigns up to C$480,000, subject to TSXV acceptance.
NurExone (OTCQB: NRXBF) announced that its U.S. subsidiary Exo-Top has signed a binding MOU with Made Scientific to create an exclusive U.S. GMP manufacturing and commercial exosome supply partnership. Made Scientific operates a 60,000-square-foot, U.S. FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey.
The parties intend to start technology transfer immediately and target first GMP exosome batches in H1 2027, supporting NurExone’s clinical pipeline and planned commercial production, including lead candidate ExoPTEN. The MOU contemplates a definitive agreement with an initial five-year term and options for additional five-year renewals, and will terminate automatically if no definitive agreement is executed within six months. NurExone also disclosed that Exo-Top and BioXtek mutually agreed not to proceed with their earlier non-binding LOI, aligning U.S. GMP exosome manufacturing under the proposed Made Scientific collaboration.